Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this...

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the tr...

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
Associated Therapies
-
Clinical Trials
Related News

Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: DVS SR
Drug: Paroxetine
First Posted Date
2007-03-09
Last Posted Date
2013-11-03
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
807
Registration Number
NCT00445679

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

Phase 4
Terminated
Conditions
Depression
Interventions
Drug: Paroxetine
Drug: Bupropion
First Posted Date
2007-01-31
Last Posted Date
2018-10-30
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
101
Registration Number
NCT00429169
Locations
🇺🇸

Columbia University/New York State Psychiatric Institute, New York, New York, United States

MDD POC Study GSK372475 Subjects Depressive Disease

First Posted Date
2007-01-11
Last Posted Date
2018-02-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
492
Registration Number
NCT00420641
Locations
🇵🇱

GSK Investigational Site, Leszno, Poland

Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities

Phase 3
Completed
Conditions
PTSD
Interventions
Drug: Paroxetine
First Posted Date
2006-11-23
Last Posted Date
2018-07-02
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
38
Registration Number
NCT00403455
Locations
🇺🇸

Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States

Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide

Phase 3
Terminated
Conditions
Major Depressive Disorder
Interventions
Drug: lithium
Drug: paroxetine
First Posted Date
2006-11-16
Last Posted Date
2021-01-29
Lead Sponsor
Nova Scotia Health Authority
Target Recruit Count
2
Registration Number
NCT00400088
Locations
🇨🇦

Capital District Health Authority - Dept. of Psychiatry, Halifax, Nova Scotia, Canada

Treatment Of Patients With Social Anxiety Disorder

Phase 2
Completed
Conditions
Social Phobia
First Posted Date
2006-11-09
Last Posted Date
2017-07-11
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
299
Registration Number
NCT00397722
Locations
🇸🇪

GSK Investigational Site, Uppsala, Sweden

SSRI Effects on Semen Parameters in Men

Completed
Conditions
Healthy
First Posted Date
2006-10-11
Last Posted Date
2017-08-02
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
35
Registration Number
NCT00385762
Locations
🇺🇸

Department of Urology, Weill Medical College of Cornell University, New York, New York, United States

An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder

First Posted Date
2006-09-08
Last Posted Date
2016-05-25
Lead Sponsor
Sanofi
Target Recruit Count
325
Registration Number
NCT00374166
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine

Phase 4
Completed
Conditions
Major Depression
First Posted Date
2006-07-27
Last Posted Date
2006-07-27
Lead Sponsor
Portland VA Medical Center
Registration Number
NCT00357045

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
First Posted Date
2006-07-13
Last Posted Date
2011-01-26
Lead Sponsor
AstraZeneca
Target Recruit Count
494
Registration Number
NCT00351910
Locations
🇸🇪

Research Site, Uppsala, Sweden

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy